TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24631983

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 40
Study: 22464408

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OC)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Nonhormonal (NH) birth control
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Hormonal contraception (OC and DMPA)
Number of subjects: 703
Study: 20709667

Group type: EXPERIMENTAL
Intervention: NMSG 4/90
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: NMSG 5/94
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: NMSG 7/98
Number of subjects: 1271

Group type: COMPARATOR
Intervention: Swedish patients
Number of subjects: 1271

Group type: EXPERIMENTAL
Intervention: Danish patients
Number of subjects: 1271
Study: 18232242

Group type: EXPERIMENTAL
Intervention: Advanced Illness Care Teams (AICTs)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 118
Study: 15860827

Group type: EXPERIMENTAL
Intervention: Daily oral supplementation using 1000 mg calcium with 800 IU cholecalciferol and information leaflet on dietary calcium intake and prevention of falls
Number of subjects: 3314

Group type: COMPARATOR
Intervention: Leaflet only (control group)
Number of subjects: 3314
Study: 15515549

Group type: EXPERIMENTAL
Intervention: bFGF injected into tympanic cavity
Number of subjects: 40
Study: 9685824

Group type: EXPERIMENTAL
Intervention: Computer-assisted diagnosis (CAD) system
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Screening radiologist with CAD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clinical radiologist with CAD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Expert screener
Number of subjects: 120

Group type: COMPARATOR
Intervention: Screening radiologist without CAD
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clinical radiologist without CAD
Number of subjects: 120
Study: 8017639

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 36

Group type: COMPARATOR
Intervention: AVP type V1 antagonist (AVPA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Enalapril (1.25 mg intravenous)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Enalapril (1.25 mg intravenous) + AVPA (0.5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intramuscular lidocaine (control)
Number of subjects: 36
Study: 2642789

Group type: EXPERIMENTAL
Intervention: Stapled anastomoses
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sutured anastomoses
Number of subjects: 73
Study: 1066224

Group type: EXPERIMENTAL
Intervention: Local anesthetics (3.6 ml submucous injection)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30664012

Group type: COMPARATOR
Intervention: Continuous infusion of 0.2% levobupivacaine (5 ml/h)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion of 0.2% levobupivacaine (15 ml every 3h)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Programmed intermittent bolus infusion of 0.2% levobupivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous infusion of 0.2% levobupivacaine
Number of subjects: 70
Study: 28400355

Group type: EXPERIMENTAL
Intervention: CBT-I delivered via the Sleepcare mobile phone app
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 151
Study: 25932549

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab 0.16 mg/0.05 mL
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 62
Study: 23798671

Group type: EXPERIMENTAL
Intervention: Rifaximin 25 mg once daily for 5 days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 21730219

Group type: EXPERIMENTAL
Intervention: High-GL meals
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-GI meals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-GL meals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low-GI meals
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cortisol responses
Number of subjects: 10

Group type: COMPARATOR
Intervention: GI × GL interactions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Effect modification by gender
Number of subjects: 10
Study: 19891018

Group type: EXPERIMENTAL
Intervention: CO(2) insufflation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard air insufflation
Number of subjects: 120
Study: 17023279

Group type: EXPERIMENTAL
Intervention: Preoperative multiple-injection thoracic paravertebral blocks (PVB group, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Preoperative multiple subcutaneous saline injections (Control group, n = 25)
Number of subjects: 50
Study: 12742881

Group type: EXPERIMENTAL
Intervention: Assessment and referral (A/R) at every visit (every 2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment and referral (A/R) every 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Assessment and referral (A/R) every visit to children found to be behind at 8 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no A/R)
Number of subjects: 0
Study: 10705321

Group type: EXPERIMENTAL
Intervention: Tourniquet use (300 mm Hg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No tourniquet use
Number of subjects: 120
Study: 9337499

Group type: EXPERIMENTAL
Intervention: Behavioral treatment (voucher incentive program and community reinforcement approach)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard treatment (lifestyle counseling)
Number of subjects: 39
Study: 7940610

Group type: EXPERIMENTAL
Intervention: Cultured epidermal allografts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated identical wounds
Number of subjects: 0
Study: 3527305

Group type: EXPERIMENTAL
Intervention: Aminoglutethimide (AG) 1.000 mg/day with hydrocortisone (HC) 20‐40 mg/day
Number of subjects: 338

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study: 30661672

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55
Study: 30022252

Group type: EXPERIMENTAL
Intervention: 50% autologous serum drops (ASD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional artificial tears (CAT)
Number of subjects: 50
Study: 27567350

Group type: EXPERIMENTAL
Intervention: DHAKA score
Number of subjects: 496

Group type: COMPARATOR
Intervention: IMCI algorithm
Number of subjects: 496
Study: 24906582

Group type: EXPERIMENTAL
Intervention: Treatment as usual plus yoga
Number of subjects: 18

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 18
Study: 21833588

Group type: EXPERIMENTAL
Intervention: Three cycles of 75 mg/m² cisplatin plus 75 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm A)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Three cycles of 25 mg/m² cisplatin plus 25 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm B)
Number of subjects: 88
Study: 19391537

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 139

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 139
Study: 17466852

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 4 times daily for 3 days preoperatively and 1 month postoperatively
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Topical indomethacin 4 times daily for 1 month postoperatively
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group receiving only topical steroids and antibiotics
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Topical indomethacin preoperatively
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Topical indomethacin postoperatively
Number of subjects: 179
Study: 16326294

Group type: EXPERIMENTAL
Intervention: Topical valdecoxib
Number of subjects: 53

Group type: COMPARATOR
Intervention: Liquid paraffin (Control)
Number of subjects: 53
Study: 12176795

Group type: EXPERIMENTAL
Intervention: RPR 109881A (1-hour infusion)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: RPR 109881A (3-hour infusion)
Number of subjects: 63
Study: 9447850

Group type: EXPERIMENTAL
Intervention: Atenolol (0, 5, or 10 mg intravenously before induction of anesthesia and every 12 h after operation until the patient could take oral medications; 0, 50, or 100 mg orally once a day as specified by blood pressure and heart rate)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7545256

Group type: EXPERIMENTAL
Intervention: P-glycoprotein (P-gly) staining in AFP-producing gastric cancers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: P-gly positivity in AFP-positive cases
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: P-gly expression in diploid tumors
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall findings regarding P-gly in AFP producing gastric carcinoma
Number of subjects: 40
Study: 2576322

Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Neuroleptic treatment
Number of subjects: 32
Study: 776538

Group type: EXPERIMENTAL
Intervention: Lysometra (2.5 ml intramuscular injections for three 20-day courses)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Methylandrostendiol (5 mg intramuscular injections for three 20-day courses)
Number of subjects: 200
Study: 31050109

Group type: EXPERIMENTAL
Intervention: iGlarLixi 5 U/5 μg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iGlarLixi 10 U/10 μg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin glargine 5 U
Number of subjects: 20
Study: 28963150

Group type: EXPERIMENTAL
Intervention: Ceramic-on-metal (CoM)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Metal-on-metal (MoM)
Number of subjects: 67
Study: 25408222

Group type: EXPERIMENTAL
Intervention: Macushield (10 mg meso‐zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (sunflower oil)
Number of subjects: 31
Study: 23338109

Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mg/kg with Nitroglycerin 200 µg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lidocaine 3 mg/kg
Number of subjects: 40
Study: 20628825

Group type: EXPERIMENTAL
Intervention: CPAP (mean pressure, 16.4 cm H(2)O)
Number of subjects: 12

Group type: COMPARATOR
Intervention: APAP (ResMed S8 Autoset II)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 12

Group type: COMPARATOR
Intervention: APAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CPAP and APAP
Number of subjects: 12
Study: 18314091

Group type: EXPERIMENTAL
Intervention: Participatory ergonomic intervention process
Number of subjects: 59
Study: 16446342

Group type: EXPERIMENTAL
Intervention: Nitroglycerin plus vinorelbine and cisplatin (arm A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Vinorelbine and cisplatin alone (placebo patch, arm B)
Number of subjects: 120
Study: 15644588

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pravastatin (20 mg/day)
Number of subjects: 47
Study: 11694666

Group type: EXPERIMENTAL
Intervention: Cod liver oil (n-3 long-chain PUFAs)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Corn oil (n-6 long-chain PUFAs)
Number of subjects: 590
Study: 9466165

Group type: EXPERIMENTAL
Intervention: RS-8359
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RS-8359 (multiple doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RS-8359 (single dose)
Number of subjects: 0
Study: 8187308

Group type: EXPERIMENTAL
Intervention: 500 micrograms lanreotide
Number of subjects: 4

Group type: COMPARATOR
Intervention: 150 micrograms octreotide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 30 mg lanreotide (SR-L)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Long-term treatment with SR-L (2-3 injections/month for 3-6 months)
Number of subjects: 4
Study: 3034318

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + HCTZ 25 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: HCTZ 25 mg + Captopril 50 mg once daily
Number of subjects: 25
Study: 29066219

Group type: EXPERIMENTAL
Intervention: One bag system
Number of subjects: 30

Group type: COMPARATOR
Intervention: Two bag system
Number of subjects: 30
Study: 26160226

Group type: EXPERIMENTAL
Intervention: Planning intervention
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Self-efficacy intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study: 25595413

Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulative therapy (SMT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham thoracic SMT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (Thoracic SMT and Sham SMT)
Number of subjects: 45
Study: 22968743

Group type: EXPERIMENTAL
Intervention: Patients with documented CAD
Number of subjects: 4133

Group type: COMPARATOR
Intervention: Patients without documented CAD
Number of subjects: 4133
Study: 19819530

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg and standard analgesia (tylenol with codeine)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard analgesia only
Number of subjects: 78
Study: 18154772

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 15947595

Group type: EXPERIMENTAL
Intervention: Screening arm (Prostate specific antigen testing, digital rectal examination, transrectal ultrasound, sextant biopsies)
Number of subjects: 35148

Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned, only yearly linkage with the Rotterdam Cancer Registry)
Number of subjects: 35148
Study: 14638545

Group type: EXPERIMENTAL
Intervention: Renal insufficiency (CrCl ≤60 mL/min)
Number of subjects: 2082
Study: 11409184

Group type: EXPERIMENTAL
Intervention: Oral doxofylline (400 mg BID)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 14
Study: 8900084

Group type: EXPERIMENTAL
Intervention: Coming Out Issues Group (10-week educational-experiential group intervention)
Number of subjects: 0
Study: 1899136

Group type: EXPERIMENTAL
Intervention: Levonorgestrel IUD (20 micrograms daily)
Number of subjects: 2758

Group type: COMPARATOR
Intervention: Copper-releasing IUD (Nova-T)
Number of subjects: 2758
Study: 6355069

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31340528

Group type: COMPARATOR
Intervention: Coaching group
Number of subjects: 288

Group type: COMPARATOR
Intervention: Coaching and SMS group
Number of subjects: 288
Study: 28612894

Group type: EXPERIMENTAL
Intervention: iProcto consultation (group A)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Regular consultation (group B)
Number of subjects: 126
Study: 26330052

Group type: EXPERIMENTAL
Intervention: High-potency topical agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional differences in topical use
Number of subjects: 0
Study: 25155203

Group type: EXPERIMENTAL
Intervention: Acromioplasty, tenotomy, and tendon suture (CR group, n=54)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Acromioplasty and tenotomy (AT group, n=49)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Tendon healing (CR group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Acromioplasty and tenotomy (AT group)
Number of subjects: 103
Study: 22192731

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2, erlotinib 100 mg daily)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Chemotherapy alone (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib (for cholangiocarcinoma subgroup)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Chemotherapy alone (for cholangiocarcinoma subgroup)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Both groups (overall survival)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus erlotinib
Number of subjects: 268
Study: 19880529

Group type: EXPERIMENTAL
Intervention: Pragmatic randomised controlled trials
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Commuting to work by the trial team
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Study centres' fuel use
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Trial team related travel
Number of subjects: 4800

Group type: EXPERIMENTAL
Intervention: Participant related travel
Number of subjects: 4800
Study: 18250616

Group type: EXPERIMENTAL
Intervention: FREMS
Number of subjects: 20

Group type: COMPARATOR
Intervention: TENS
Number of subjects: 20
Study: 16358997

Group type: EXPERIMENTAL
Intervention: Low dose rofecoxib combined with simvastatin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Simvastatin alone
Number of subjects: 29
Study: 16310019

Group type: EXPERIMENTAL
Intervention: BWLP+SC (behavioral weight loss program with stepped-care approach)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BWLP+SC [PST] (behavioral weight loss program with stepped-care approach including problem-solving therapy)
Number of subjects: 44

Group type: COMPARATOR
Intervention: BWLP (behavioral weight loss program without stepped-care approach)
Number of subjects: 44
Study: 10371567

Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (28,628 women offered screening)
Number of subjects: 54654

Group type: COMPARATOR
Intervention: Control group (26,026 women)
Number of subjects: 54654

Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (after SES adjustment)
Number of subjects: 54654

Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (censoring deaths after diagnosis more than 3 years post-study)
Number of subjects: 54654

Group type: EXPERIMENTAL
Intervention: Breast-cancer screening intervention group (younger than 50 years)
Number of subjects: 54654

Group type: COMPARATOR
Intervention: Control group (other-cause mortality)
Number of subjects: 54654
Study: 8701447

Group type: EXPERIMENTAL
Intervention: Technical aids provided (average of three out of five advised)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Technical aids provided
Number of subjects: 83
Study: 1992599

Group type: EXPERIMENTAL
Intervention: Nilutamide (300 mg/day) plus buserelin
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Castration plus nilutamide
Number of subjects: 248

Group type: COMPARATOR
Intervention: Castration plus placebo
Number of subjects: 248
Study: 6357890

Group type: EXPERIMENTAL
Intervention: 75 mg intramuscular diclofenac sodium (Voltaren)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 131
Study: 30831335

Group type: EXPERIMENTAL
Intervention: Focusing on one's own appearance (appearance group)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Writing about personality (personality group)
Number of subjects: 263
Study: 30203750

Group type: EXPERIMENTAL
Intervention: Celecoxib therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Diclofenac sodium therapy
Number of subjects: 180
Study: 26571037

Group type: EXPERIMENTAL
Intervention: 20% mannitol
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3% hypertonic saline (HS)
Number of subjects: 60
Study: 25246338

Group type: EXPERIMENTAL
Intervention: Co-infusion of donor adipose-derived mesenchymal stem cells (AD-MSC) + hematopoietic stem cells (HSC)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cells (HSC)
Number of subjects: 285

Group type: COMPARATOR
Intervention: No stem cell therapy (Control group)
Number of subjects: 285
Study: 22504039

Group type: EXPERIMENTAL
Intervention: MenACWY-CRM + MMRV
Number of subjects: 100

Group type: COMPARATOR
Intervention: MenACWY-CRM
Number of subjects: 100

Group type: COMPARATOR
Intervention: MMRV
Number of subjects: 100
Study: 20102716

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg, orally, 3 times daily)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 17907108

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Tesaglitazar
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Tesaglitazar and pioglitazone
Number of subjects: 1707
Study: 16135350

Group type: EXPERIMENTAL
Intervention: Proximal motor response (group PROX)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Distal motor response (group DIST)
Number of subjects: 150
Study: 11966970

Group type: EXPERIMENTAL
Intervention: Exercise therapy (active and passive jaw movement exercises, correction of body posture, relaxation techniques)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waiting-list control (no treatment)
Number of subjects: 20
Study: 10194424

Group type: EXPERIMENTAL
Intervention: Filgrastim and cladribine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cladribine alone
Number of subjects: 35
Study: 7594322

Group type: EXPERIMENTAL
Intervention: Lansoprazole plus low-dose amoxicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lansoprazole monotherapy
Number of subjects: 0
Study: 31743412

Group type: EXPERIMENTAL
Intervention: Arrowhead Business Group (ABG) entrepreneurship education intervention; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison with other youth from the participating tribal community and state; details on intervention/control not available.
Number of subjects: 0
Study: 30400355

Group type: EXPERIMENTAL
Intervention: North area dietary intake
Number of subjects: 6646

Group type: EXPERIMENTAL
Intervention: North area nutrient intake
Number of subjects: 6646

Group type: EXPERIMENTAL
Intervention: Sex, smoking status, and physical activity
Number of subjects: 6646
Study: 26123678

Group type: EXPERIMENTAL
Intervention: Home-based smoking prevention programme 'Smoke-free Kids'
Number of subjects: 1398

Group type: COMPARATOR
Intervention: Control condition (fact-based programme)
Number of subjects: 1398